The prediction was that by blocking RIOK1, we could promote the cell susceptibility required for apoptosis and mark RIOK1 as a potential anticancer therapy, representing a new strategy for targeting CRC MSI-High p53-Mut cell lines. This evidence concerns the gene TP53 and colorectal carcinoma.